Literature DB >> 25154546

Clinical and immunological profiles of 25 patients with pemphigoid gestationis.

N Tani1, Y Kimura, H Koga, T Kawakami, C Ohata, N Ishii, T Hashimoto.   

Abstract

BACKGROUND: Systematic study of pemphigoid gestationis (PG) has not been performed owing to its rarity.
OBJECTIVES: To perform clinical and immunological analyses of 25 patients with PG.
METHODS: In addition to clinical and histopathological assessments, we performed immunofluorescence (IF), immunoblotting (IB) and enzyme-linked immunosorbent assays (ELISAs).
RESULTS: PG developed preferentially during the second or third trimester of pregnancy, with a mean age at onset of 30·5 years. Histopathology showed subepidermal blisters less frequently. Direct IF showed C3 deposition in the basement membrane zone (BMZ) in all patients, with rare reactivity with keratinocyte cell surfaces. Ninety-two per cent of patients showed circulating IgG anti-BMZ autoantibodies during indirect IF of either normal or 1 mol L(-1) NaCl-split skin. Complement IF revealed linear C3 reactivity with the BMZ of normal skin in 68% of patients, and all patients had C3 reactivity on the epidermal side of 1 mol L(-1) NaCl-split skin. IB and ELISA of the NC16a domain of BP180 recombinant protein was positive in 96% and 92% of patients, respectively, while only four patients had a positive ELISA for BP230. In IB tests, 28% of patients reacted with the C-terminal domain of BP180 and 20% reacted with leucocyte adhesion deficiency-1 protein. Multigravidae developed PG during a significantly (P < 0·01) earlier stage (21·1 weeks) of pregnancy than primigravidae (31·3 weeks).
CONCLUSIONS: IB and ELISA of the NC16a domain of BP180 were shown to be sensitive and diagnostic methods in PG. Patients with PG rarely reacted with BP230, suggesting a different pathogenesis between PG and bullous pemphigoid. Multigravidae developed PG skin lesions significantly earlier in pregnancy than primigravidae.
© 2014 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25154546     DOI: 10.1111/bjd.13374

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  8 in total

Review 1.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

2.  A resistant case of pemphigus gestationis successfully treated with cyclosporine.

Authors:  Özhan Özdemir; Cemal Resat Atalay; Vusala Asgarova; Bunyamin Ugur Ilgin
Journal:  Interv Med Appl Sci       Date:  2016-03

Review 3.  Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

Review 4.  Pemphigoid gestationis: current perspectives.

Authors:  Christine Sävervall; Freja Lærke Sand; Simon Francis Thomsen
Journal:  Clin Cosmet Investig Dermatol       Date:  2017-11-08

5.  Diagnosis, fetal risk and treatment of pemphigoid gestationis in pregnancy: A case report.

Authors:  Hai-Ning Jiao; Ye-Ping Ruan; Yan Liu; Meng Pan; Hui-Ping Zhong
Journal:  World J Clin Cases       Date:  2021-12-06       Impact factor: 1.337

Review 6.  Pruritus in Pregnancy.

Authors:  Aleksandra A Stefaniak; Manuel P Pereira; Claudia Zeidler; Sonja Ständer
Journal:  Am J Clin Dermatol       Date:  2022-02-21       Impact factor: 7.403

Review 7.  Type XVII collagen: Relevance of distinct epitopes, complement-independent effects, and association with neurological disorders in pemphigoid disorders.

Authors:  Bianca Opelka; Enno Schmidt; Stephanie Goletz
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

8.  Pemphigoid gestationis: Clinical and histologic features of twenty-three patients.

Authors:  Z Hallaji; H Mortazavi; S Ashtari; A Nikoo; M Abdollahi; M Nasimi
Journal:  Int J Womens Dermatol       Date:  2016-12-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.